New York, NY - Kyowa Hakko has commenced manufacturing Coenzyme Q10 (CoQ10) at its production facility in Hofu, Japan, and re-launched sales of Kyowa CoQ10™ to the U.S. nutraceutical marketplace. Kyowa Hakko is an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products.
A pioneer in the development and application of fermentation technology, Kyowa Hakko has maintained a constant commitment to research and developing innovative products. Kyowa has developed a patented non-yeast fermentation technology that meets USP, JP and EP requirements to provide a unique and cost effective CoQ10 product.
Kyowa, supplying CoQ10 globally, became the original marketer of CoQ10 in the U.S. nutraceutical industry in 1985. From 1994 to 2000, Kyowa dominated the CoQ10 category and controlled 50% of the marketplace.
"Kyowa CoQ10 is a significant ingredient with mutual benefits for manufacturers seeking to enhance their dietary supplement products geared to millions of health conscious consumers," said Charlie Kotani, president, Kyowa Hakko USA.
A fat-soluble substance found naturally in all forms of animal life, CoQ10 is localized in the membranes of cells and is vital in the production of energy. Considered the power plant of the human body, it has especially high concentration in the heart, the organ that requires high levels of energy for normal operation.
CoQ10 is used as a dietary supplement, with the popular rationale that boosting intake of the nutrient could support cellular metabolism, particularly in cells with energy deficiencies.
Kyowa Hakko, maker of the branded ingredients Cognizin™ Citicoline, Hydrafend™ and Lumistor™, also offers manufacturers and formulators one of the industry's most extensive lines of over 50 amino acids and related compounds, including D-Amino acids and branch-chain amino acids, as well as nucleic acids, bio-products and fine chemicals.